同濟堂(600090.SH)擬發行不超10億元超短期融資券
格隆匯2月14日丨同濟堂(600090.SH)公佈,為降低融資成本,優化融資結構,增加資金流動性管理,根據中國人民銀行《銀行間債券市場非金融企業債務融資工具管理辦法》、《銀行間債券市場非金融企業超短期融資券業務指引》等有關規定並結合公司業務發展的需要,公司(“發行人”)擬向中國銀行間市場交易商協會申請註冊發行不超過10億元超短期融資券(“超短融”),此次募集資金用途:用於採購醫藥、醫療物資的流動資金、營運資金、償還有息債務及其他中國銀行間市場交易商協會認可的用途;發行期限:單期發行期限為最長不超過270天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.